International Stem Cell Corporation Completes $5 Million Financing and Elects Jim Berglund to the Board of Directors

CARLSBAD, Calif. (March 12, 2012) – International Stem Cell Corporation (OTCBB:ISCO) www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic, cosmetic and research products, announced today that it had obtained new capital financing and made important changes in the composition of its Board of Directors to ensure that Independent Directors hold the majority of Board seats.

The financing consists of $5 million in newly issued Series G Convertible Preferred Stock (without warrants), convertible into Common Stock at a conversion price of $0.40/share, the market price of the Company’s Common Stock on the date the offer to purchase was made.  This financing was made by AR Partners LLC, a healthcare investment firm owned by Dr. Andrey Semechkin ISCO’s CEO and Co-Chairman of the Board of Directors.

Concurrently with the closing of this financing, the Company elected to its Board of Directors Dr. James Berglund, co-founder of Enterprise Partners Venture Capital - one of the premier venture capital firms in the field of healthcare technology founded in 1985. Dr. Berglund, with his extensive professional experience, continues as an active participant in the biotech and healthcare industries. Dr. Berglund will replace Kenneth C. Aldrich, co-founder and former CEO of the Company during the period 2008-2009, who is stepping down as ISCO Board of Directors Co-Chairman. Although Mr. Aldrich is retiring from our Board, he will remain as one of ISCO’s largest shareholders and an active consultant to the Board and executive management and will continue to represent the Company as “Chairman Emeritus” in a variety of public and private venues.

According to Mr. Aldrich, “In my view, Dr. Semechkin’s willingness to commit such a significant amount of capital to ISCO at the market price of the Company’s stock on the date of his offer represents a major vote of confidence in ISCO’s future by its most senior executive. We are thankful to Dr. Semechkin for his support that will further advance ISCO’s parthenogenetic stem cell-based therapeutic programs and income generating businesses.”

Having a majority of independent directors on our company’s Board represents an important step in ISCO’s development and in transforming ISCO into a leading public company in the field of regenerative medicine.

“I want to thank Mr. Aldrich for his long-standing dedication and continued involvement in guiding the Company,” said Dr. Semechkin. “This long-term investment, along with the new executive management team recruited over the previous twelve months, will provide ISCO with the necessary economic stability and resources to pursue its goals of consolidating our leadership position and accelerating our therapeutic programs” continued Dr. Semechkin.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products.  ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). HpSCs avoid ethical issues associated with the use or destruction of viable human embryos.  ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial backgrounds.  This offers the potential to create the first true stem cell bank, UniStemCell™.  ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care.  More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation

Andrey Semechkin, Co-Chairman and CEO

760-940-6383

aes@intlstemcell.com

Kurt May, President/COO

760-940-6383

kmay@intlstemcell.com

Lippert/Heilshorn & Associates 

Don Markley (dmarkley@lhai.com)

310-691-7100

International Stem Cell Corporation - "How Is Parthenogenesis Done?"

San Diego Research Ethics ConsortiumSalk Institute for Biological Studies

Parthenogenetic stem cell lines:  Ethical considerations

International Stem Cell’s Director of Research and Therapeutic Development, Nikolay Turovets, PhD, presents “How is Parthenogenesis Done?”

How is Parthenogenesis Done? (ANIMATED)

Listen to International Stem Cell Corporation's November 17th Business Update Conference Call

To listen to International Stem Cell Corporation's November 17th Business Update Conference Call, please click HERE

International Stem Cell Corporation's Kenneth Aldrich - The Wall Street Transcript

If trouble viewing, please click here - International Stem Cell - TWST

International Stem Cell to Hold Business Update Conference Call on November 17th 10am PST/1pm EST

International Stem Cell Corporation (OTCBB: ISCO) today announced that it will hold a conference call and webcast on Thursday, November 17, 2011 at 1:00 p.m. Eastern (10:00 a.m. Pacific). President and Chief Operating Officer Kurt May and Co-Chairman Ken Aldrich will provide an update on the business, including a discussion of recently announced third quarter results.

Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers, or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.intlstemcell.com.

A telephone replay will be available approximately one hour after the conclusion of the call by dialing (877) 660-6853 for domestic callers, or 201-612-7415 for international callers, and entering the account code: 286 and the Conference ID: 383602. The webcast will be available on the Company's Web site for 60 days following the completion of the call.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .

International Stem Cell Corporation

Kenneth C. Aldrich, Chairman

760-940-6383

kaldrich@intlstemcell.com

or

LHA

Don Markley

310-691-7100

dmarkley@lhai.com

Letter to the International Stem Cell Corporation Shareholders and Followers

To the shareholders and followers of International Stem Cell Corporation:

You’ve likely seen stem cells in the news recently, and we’d like to take an opportunity to give you our views on two of the recent announcements. 

First, International Stem Cell Corporation announced yesterday earnings for the third quarter 2011.  We’ll be hosting a conference call on Thursday, November 17, 2011 at 10:00 AM PST to discuss key developments in the quarter, provide our outlook and answer your questions.   Individuals interested in listening to the conference call may do so by dialing 877-407-8033 for domestic callers or 201-689-8033 for international callers, or from the webcast on the investor relations section of the Company’s Web site at www.internationalstemcell.com. 

Second, Geron’s decision, announced yesterday, to terminate its stem cell R&D program in no way affects ISCO’s current strategy or developmental activities, nor does it alter our optimism for the potential of stem cells to eventually treat a broad-range of diseases and conditions.  While Geron may be reprioritizing programs, we are committed to the course we are on. 

Additionally, ISCO will continue its discussions with CIRM regarding possible funding for our truly unique parthenogenesis technology, particularly in light of the $25 million previously earmarked for Geron coming available for other investments.

Thank you for your interest in ISCO.  We hope you will join us for the conference call.

Sincerely,

Ken Aldrich

International Stem Cell Corporation Announces Third Quarter 2011 Financial Results

CARLSBAD, California – November 15, 2011 - International Stem Cell Corporation (ISCO) (OTCBB:ISCO) today announced financial results for the three-month and nine-month periods ended September 30, 2011.  ISCO is a development-stage biotechnology company that created, patented and is commercializing a powerful new stem cell technology called parthenogenesis which promises to advance significantly the field of regenerative medicine.

ISCO reported revenue of $0.84 million for the quarter ended September 30, 2011, a 141% increase from the same period of the prior year.  For the nine months ended September 30, 2011, the Company reported revenue of $3.47 million, a year-over-year increase of 227%.  The increases in revenue was driven by strong sales from the initial launch of ISCO’s wholly-owned subsidiary Lifeline Skin Care (LSC), which commenced operations in the fourth quarter of 2010.  In addition, steady growth in sales from ISCO’s other wholly-owned subsidiary, Lifeline Cell Technology (LCT), contributed to the increases in revenues for both periods. 

The Company continued to invest in the development of new technologies, products and channels of distribution.  For the three months ended September 30, 2011, development expenses, excluding cost of sales, were $3.60 million, an increase of 15% compared to the third quarter of 2010, reflecting increased R&D activities on therapeutic programs and new product development for both subsidiaries.  Sales and marketing expenses related to our skin care products, partially offset by a reduction in general and administration expenses, also contributed to the increase in development expenses.

For the nine months ended September 30, 2011, development expenses, excluding cost of sales, were $10.77 million, an increase of 30% when compared with the prior year period.   The increase is attributed primarily to increased research activities on therapeutic products and product development programs for LSC and LCT, increased stock-based compensation expense, increased headcount and higher general corporate expenses coupled with increased sales and marketing expenses related to our skin care products.

Dr. Andrey Semechkin, co-Chairman and CEO, commented “We are pleased with the rapid growth in sales of our two subsidiaries, LSC and LCT.  Together, these business units are providing much-needed capital to help support our growth as well as the research leading to the development of new stem cell technologies and products.”   Kurt May, President and COO, noted “Our focus continues to be on maximizing the performance of our operating subsidiaries,  advancing the development and commercialization of our therapeutic products and strengthening our organization and operating systems to accommodate our anticipated rapid and significant growth.”

Third Quarter 2011 Highlights:

Important developments and milestones for International Stem Cell in the third quarter included:

-- Continuing to solidify its leadership team with the addition of Linh Nguyen as ISCO’s new Chief Financial Officer.  Further, the Board of Directors elevated Kurt May to President and Chief Operating Officer and Dr. Semechkin to co-Chairman of the Board and Chief Executive Officer.

-- Renewing the marketing agreement with John Mauldin to promote its Lifeline Skin Care products and commenced a new sales channel to resorts and destination spas.

-- Lifeline Cell Technology began selling products through new distribution channels in Japan, Korea, Singapore, Malaysia and Indonesia, expanding its business throughout Asia.

-- ISCO scientists successfully completed the first series of preclinical studies designed to support the application of neuronal cells derived from hpSCs.  These experiments were designed to demonstrate that the derived neuronal cells were able to survive in mouse brains without giving rise to tumors.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products.  ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos.  ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation.  hpSCs offer the potential to create the first true stem cell bank, UniStemCell™.  ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care.  More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, anticipated sales growth and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation

Andrey Semechkin, CEO & Co-Chairman

760-940-6383

aes@intlstemcell.com

International Stem Cell Corporation

Kurt May, President & COO

760-710-3294

kmay@intlstemcell.com

International Stem Cell Corporation

Linh Nguyen, CFO

760-940-6383

LNguyen@intlstemcell.com

Lippert/Heilshorn & Associates

Don Markley

310-691-7100

dmarkley@lhai.com

Please click on the pages below to enlarge.

1) The Company restated its financial statements for the year ended December 31, 2010 and the quarter ended March 31, 2011. See explanatory note after cover page of this 10-Q and Note 1 to the unaudited condensed consolidated financial statements.  See accompanying notes to the unaudited condensed consolidated financial statements

California Stem Cell Report Article: “Trounson, Parthenotes and International Stem Cell”

Source: http://californiastemcellreport.blogspot.com/2011/11/trounson-parthenotes-and-international.html

The president of the California Stem Cell Agency, Alan Trounson, popped up in a recent article in Scientific American dealing with a method for creating pluripotent stem cells from unfertilized human eggs. 

The piece by Julia Galef said that "many investigators remain frustrated" that the method "remains offlimits" for federal funding, a barrier that does not apply to financing from the $3 billion California stem cell agency. 

Galef wrote that one California firm, International Stem Cell Corp., of Carlsbad, is using the method to develop products. She said the firm's work involves "a process called parthenogenesis, in which researchers use chemicals to induce the egg to begin developing as if it had been fertilized. The egg—called a parthenote—behaves just like an embryo in the early stages of division. Because it contains no genetic material from a father, however, it cannot develop into a viable fetus." 

To read the complete article on "California Stem Cell Report", please click here  

International Stem Cell's Research Scientists Successfully Completed the First Series of Preclinical Animal Trials of Neuronal Cells

International Stem Cell Corporation (OTCBB: ISCO) announces today successful completion of the first series of preclinical studies designed to support the safety and utility of neuronal cells derived from human parthenogenetic stem cell line (hpSC). These initial experiments, demonstrating that the derived neuronal cells were able to survive in mice brains without giving rise to tumors, represent a key milestone towards possible therapeutic applications including treating Parkinson's disease.


Dr. Albrecht Müller, Professor at the Institute of Medical Radiology and Cell Research, Würzburg University (Germany), commented: "Human parthenogenetic stem cells are potentially very promising candidates for use in regenerative medicine primarily because of the possibility that they immune-match a large number of recipients. The result of these safety and survival studies is a very important step along the path towards the clinical use of such cells."


Although most cases of Parkinson's disease occur in people with no family history of the disease, a number of genetic mutations have nevertheless been identified with the disease. While the inheritance pattern is largely unknown, as a condition with a genetic component "autologous" treatment, that is to say treatment using the patient's own cells, is far from ideal and does not offer the potential of a cure. To treat Parkinson's disease successfully a source of cells free of the mutated genes is necessary. Human parthenogenetic stem cells provide this source, as well as superior immune-matching capabilities.


ISCO currently has the world's largest collection of human parthenogenetic stem cells including heterozygous examples, where the cells immune match the donor as is the case with induced pluripotent stem cells (iPS), and homozygous examples which immune-match millions of individuals. ISCO is actively expanding this collection of cell lines and creating a "bank" of homozygous human parthenogenetic stem cells that can be used as a platform to not only reduce the chances of tissue rejection, but also make cellular-based therapies economically more viable.


Dr. Ruslan Semechkin, ISCO's Vice President, commented: "One of ISCO's main therapeutic targets is treatment of Parkinson's disease, a common neurodegenerative disease in the US, where the current standard of care is designed mostly to treat the symptoms, but not the disease. These results clearly represent an important step towards the therapeutic application of human parthenogenetic stem cells derived cells in addressing the basic underlying mechanisms and potentially transforming the treatment of neurodegenerative diseases."


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCellTM. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com 


To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


Forward-looking Statements
Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward- looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.


International Stem Cell Corporation
Kenneth C. Aldrich, co -Chairman
760-940-6383
kaldrich@intlstemcell.com
Or:
Dr. Ruslan Semechkin, Vice President
760-940-6383
ras@intlstemcell.com
Or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

International Stem Cell Corporation's Ken Aldrich Comments on Recent News about SCNT - Somatic Cell Nuclear Transfer

Last week's newspapers carried the news of what was widely described as a significant “breakthrough” in stem cell science: the first successful human use of a technology known as Somatic Cell Nuclear Transfer (also referred to as SCNT).  This is essentially a variation on a process that was used some years ago to create a cloned sheep named Dolly.  Cloning has since been used commercially in various animal applications.

What is strange about the flurry of publicity about this discovery, however, is the almost total lack of commentary about a method of creating stem cells that has been available to researchers for almost half a decade, holds the same kind of promise as embryonic stem cells for providing cells for the treatment of almost any kind of degenerative disease, is free of ethical issues (including issues with egg donation), and can potentially make immune matched cells available to any patient anywhere in the world, on demand, at a far lower cost.

I am talking about human stem cells derived from a process called, “Parthenogenesis”, developed and first announced in 2007 by a company called International Stem Cell Corporation, whose discoveries were first published in the peer reviewed journal, Cloning and Stem Cells, edited by the scientist who first created “Dolly”, the first cloned animal. 

I realize that I could be accused of bias because I am one of the founders of International Stem Cell, but, in fact, our company also owns license rights to some of the key intellectual property that is required to create cells through SCNT technology and our scientists are very familiar with its promise and its limitations. As a result, International Stem Cell will benefit from the development of either technology, but it is important that the public and the scientific community be fully aware of all alternatives in the field of regenerative medicine, not just the ones that capture public imagination at any particular time.

For that reason, I would like to comment on Parthenogenesis and compare it to SCNT technology and the other options available today. The technology known as "Parthenogenesis" begins with human eggs that are created and used every day throughout the world for in-vitro fertilization (IVF). What is not generally known is that the IVF process can often result in the creation of far more unfertilized eggs than will ever be needed for fertility purposes. It is possible, with informed consent from the IVF patient, to hold back some unfertilized eggs for creation of parthenogenetic stem cells, all at no additional risk to the donor. 

Instead of wasting those eggs, what International Stem Cell does, with the full consent of the donors, is to save those eggs from the trash bin, induce them through a simple, but patented, process to create the small cluster of cells from which a stem cell line can be created that can be used for scientific research and the eventual treatment of patients with such diseases as Parkinson’s, Macular Degeneration, Liver Disease, Diabetes, and possibly many others.

What are critical to understand in thinking about Parthenogenetic stem cells are six things:

Like embryonic stem cells and SCNT cells, these cells can be converted into almost any cell in the human body and thus have enormous potential for human therapy.

Unlike embryonic stem cells, the human eggs used to create parthenogenetic stem cells are never fertilized and cannot become a human being. No viable embryo is ever harmed or destroyed.

Unlike SCNT cells, parthenogenetic stem cells require no genetic manipulation or insertion of foreign DNA.

No donor is every subjected to any additional physical risk beyond what she has already agreed to as part of the IVF procedure in which she elected to participate. In fact, all egg donors voluntarily participate through a very transparent, peer-reviewed, and medically supervised process.  Protocols are approved by Independent Review Boards (IRBs) to protect the safety of donors and by an independent Stem Cell Research Oversight (SCRO) committee to insure compliance with state laws and research ethics, regulations established by the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services (HHS) Office for Human Research Protections, in addition to state-level requirements.

The cell lines that are produced from this method, unlike cell lines from embryonic stem cells or from SCNT, can potentially be matched to millions of people in the same way that an organ transplant is matched between donor and patient. In fact, by some estimates, as few as 100 parthenogenetic stem cell lines could provide immune-matched cells to over 50 percent of the world’s population, and could accelerate disease therapies and treatments for severe chronic conditions, including diabetes, spinal cord injuries, liver diseases, blinding diseases such as macular degeneration, and neural diseases such as Parkinson’s and Alzheimer’s.

The possibility of immune-matching to millions of persons can vastly reduce the potential costs relative to SCNT or embryonic stem cell technology, which create stem cell lines that can match only a few persons.

In summary, what we find particularly exciting about Parthenogenesis is that it addresses all the major issues of stem cell therapy. It is free from the traditional bioethical issues that have clouded federal policies towards stem cell research because parthenotes are derived from unfertilized eggs and cannot develop into human beings.  Parthenogenesis is not cloning, and it does not involve the creation or destruction of a viable human life.  Also, the creation of a parthenogenetic stem cell bank will not require a large number of human eggs and many individual donors, as has been a fear surrounding other stem cell approaches.  Parthenogenesis is at once effective and efficient, and one line of parthenogenetic stem cells can be used to create treatments for millions of persons.  This is not a situation where one line must be made for each patient treated.

To learn more about Parthenogenesis, visit www.internationalstemcell.com, or click on ISCO.OB at any financial web site for information about our company.

International Stem Cell Corp. Chairman Kenneth Aldrich Comments on Recent TIME Article “A Stem Cell First: Using the 'Dolly' Method on Human Cells”

“Since we at International Stem Cell Corporation (trading symbol: ISCO.OB) are licensees of some of the key intellectual property necessary to use SCNT in therapeutic products, we were delighted to read about this new discovery.  However, what disappointed us somewhat was the failure of most news reports to mention that a technology already exists that solves the same ethical problems and has the potential also to solve many of the problems of immune rejection that worry scientists who are working with cells obtained from fertilized embryos.

That technology is called "Parthenogenesis" and results in a "cell line" that can provide an essentially unlimited supply of human cells for a wide range of therapeutic purposes, yet does not involve the destruction of any fertilized embryo and results in cells that can be matched to large groups of people who may not even know the patient, much like the way blood from donors can be stored and used by accident victims as needed. Unlike the SCNT cells, parthenogenetic cells require no genetic manipulation or insertion of foreign DNA.

Our scientists at ISCO created and patented the process for making such human parthenogenetic stem cell lines and have already successfully made liver cells, cornea cells, retina cells and nerve cells from those cell lines.  Each of these applications is being studied as a possible future source of transplanted cells to treat diseases such as Parkinson's, Liver Disease, Macular Degeneration, and others. 

To learn more about parthenogenesis, visit our website at www.internationalstemcell.com or click on ISCO.OB at any financial web site for information about our company.”

Kenneth C. Aldrich

Chairman

International Stem Cell Corporation

TIME Article – A Stem Cell First: Using the 'Dolly' Method on Human Cells

http://healthland.time.com/2011/10/05/a-stem-cell-first-using-the-dolly-method-on-human-cells/

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 .

Forward-looking Statements

Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Representative Brian Bilbray Meets with International Stem Cell Executives to Discuss Research Funding

International Stem Cell Corporation (OTCBB: ISCO) today announced that Representative Brian Bilbray recently met with Company executives, including Chairman Kenneth Aldrich, President and Chief Executive Officer Andrey Semechkin, and Senior Vice President Kurt May, to discuss key federal government issues relating to stem cell research. Rep. Bilbray represents California's 50th congressional district, which includes portions of San Diego's North County.

Following the meeting, Rep. Bilbray stated, "I have tremendous respect for the innovative healthcare companies in my district, such as International Stem Cell, that are at the forefront of developing important new treatments and therapies. I'm committed to helping remove unnecessary regulations and barriers that may inhibit the research of new life science technologies, and I greatly appreciate the efforts of ISCO's management team to clarify many of the issues surrounding their work."

Said Dr. Semechkin, "We are very pleased to have the opportunity to meet with Congressman Bilbray and explain the importance of our parthenogenesis technology and how it differs from human embryonic stem cell development, particularly from an ethical standpoint. We look forward to continued discussions with Congressman Bilbray and his colleagues regarding the Dickey-Wicker Amendment. We believe that with increased understanding of our technology the National Institutes of Health (NIH) will support parthenogenesis research and development."

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation

Kenneth C. Aldrich, Chairman

760-940-6383

kaldrich@intlstemcell.com

or

Lippert/Heilshorn & Associates

Don Markley

310-691-7100

dmarkley@lhai.com

International Stem Cell Corporate (ISCO.OB) Produced by Big Sky Productions - 9 Minute Version

Ken Aldrich of International Stem Cell Corporation (ISCO.OB) on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body...as well as other applications. Mr. Aldrich also discusses neurological applications focusing on reversing Parkinson's disease.

This corporate video was produced by Big Sky Productions Inc. (BGSI.OB).

Executive Producer, Ellis Martin.

Producer and Creative Director, Narrator, Editor: Bob Lange

http://www.ellismartinreport.com  http://www.intlstemcell.com  

contact: bigskymedia@yahoo.com

ChartPoppers.com Interviews Kenneth Aldrich, CEO of International Stem Cell Corp. (OTCBB:ISCO)

Chartpoppers.com - The #1 rated Penny Stocks Newsletter for Penny Stock Tips, Stock Market information, Penny Stock Picks, Trading Articles, and Day Trading.

ChartPoppers.com is pleased to announce the availability of an exclusive audio interview with Kenneth Aldrich of International Stem Cell Corporation

Please click here to listen to the complete interview.

Ellis Martin Report with International Stem Cell Corporation's Senior VP Kurt May

In this interview Ellis Martin speaks with Kurt May, Senior Vice-President of International Stem Cell Corporation (ISCO.OB). Mr. May discusses his role with the company and their unique development of the parthenogenic stem cell derived from unfertilized embryonic eggs.  He oversees the growth of the company's LIfeline Stem Cell and Lifeline Skin Care revenue generating divisions. The question of immune rejection is overcome with their proprietary technology.

Listen to learn more. http:://www.intlstemcell.com http::/www.ellismartinrepot.com 
Contact: martinreports@gmail.com

International Stem Cell Corp is a paid sponsor of The Ellis Martin Report

Video: The Promising Cells Presented by International Stem Cell Corporation

Ken Aldrich of International Stem Cell Corporation (ISCO.OB) on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body...as well as other applications. Mr. Aldrich also discusses neurological applications focusing on reversing Parkinson's disease.

This corporate video was produced by Big Sky Productions Inc. (BGSI.OB).

Executive Producer: Ellis Martin

Producer and Creative Director, Narrator, Editor: Bob Lange

http://www.ellismartinreport.com  http://www.intlstemcell.com  

contact: bigskymedia@yahoo.com

Video Link - http://www.youtube.com/watch?v=CcXPMHqENys

Onemedplace.com Interview - "International Stem Cell Corp Develops Similar Embryonic Stem Cells Without Fertilized Embryos"

Ken Aldrich, Executive Chairman of International Stem Cell Corporation [OTC:ISCO] was interviewed by OneMedRadio where he discussed the company’s regenerative medicine therapies.

Brett Johnson:  Good day, this is Brett Johnson in New York City with OneMedRadio. Today, I am with Ken Aldrich. He is the co-founder and executive chairman for International Stem Cell, symbol ISCO on the bulletin board. It is a Carlsbad, California company in the stem cell business.  Ken, thanks for joining us today.

Kenneth Aldrich: Thank you. I appreciate the opportunity to speak with you.

BJ: Ken, go ahead and tell us a little bit about the business of International Stem Cell and what you guys are doing that’s unique and distinctive.

KA: I’d be happy to. International Stem Cell is in the regenerative medicine business broadly speaking. We produce and develop therapies that are based on what are called pluripotent stem cells. Pluripotent stem cell simply means a stem cell that can be converted  (the technical word is differentiated) into any cell in the body and theoretically treat any kind of disease that can be treated with cell therapy.

There are today basically only two ways to create a pluripotent stem cell. One is what’s been around for ten years called embryonic stem cells derived from a fertilized human embryo, and the other is parthenogenesis, which is our own creation, our own patent. Our people really developed it from the very beginning.

They function very much the same but we have two unique advantages. One, we take the ethical issue right off the table. We do not use a fertilized egg and we never damage or destroy anything that could become a human being. And second, the DNA that results when we go through that process of using only an unfertilized egg is a much simpler DNA structure. It’s complete, but simpler in its form. It enables us to use a single cell line from a single donor to match very large numbers of people. So it gives us the potential a few years down the road to have a true stem cell bank. And by that I don’t mean the banking of somebody’s own cells, but a bank much like a blood bank in which any patient who needs stem cells can come, get cells that will match their immune system and thereby eliminate or reduce the need for immunosuppressant drugs.

We think ultimately that’s going to be the single defining differentiator for our company because a cell transplant is like a miniature organ transplant. If the body rejects it, there’s no benefit, and we’re working on a way to provide cells that anyone can use at any time for any disease that any scientist is smart enough to figure out a way to treat with cells. It’s a tall order but we think we’re up to it.

To read the full text or listen to the interview, please visit onemedplace -http://www.onemedplace.com/blog/archives/9031